TMCnet News
Hanmi Pharmaceutical to Present Its New Targeted Lung Cancer Drug 'HM61713' at 2015 ASCO Annual MeetingHanmi Pharmaceutical co., Ltd. (KSE:128940) will present the results of the phase I/II domestic clinical trial of HM61713 in patients with EGFR mutation positive non-small cell lung cancer at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2015, in Chicago, USA. During the conference, Hanmi Pharmaceutical will participate in a session on Lung Cancer-Non-Small Cell Metastatic, and will give a poster presentation on the results of the phase I/II domestic clinical trial with 195 patients of EGFR mutation positive non-small cell lung cancer administered with HM61713. HM6113 selectively inhibits the mutation of signal delivery substance EGFR involved in the growth of cancer cells, and is evaluated as the third-generation EGFR tyrosine kinase inhibitor (TKI) which overcomes resistance and side effects after administration with previous EGFR TKIs Iressa® and Tarceva®. Presentation Schedule (local time)
HM61713 (HM-EMSI-101)
Hanmi Pharmaceutical co., Ltd.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150528005595/en/ |